I-Mab (IMAB) Scheduled to Post Quarterly Earnings on Wednesday

I-Mab (NASDAQ:IMAB) will post its quarterly earnings results before the market opens on Wednesday, August 28th. Analysts expect I-Mab to post earnings of ($0.51) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

I-Mab Trading Up 1.3 %

Shares of IMAB opened at $1.22 on Monday. The stock has a 50 day simple moving average of $1.42 and a 200 day simple moving average of $1.66. I-Mab has a 52-week low of $0.99 and a 52-week high of $2.54.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.